These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 31251112)

  • 21. STEIN: A simple toxicity and efficacy interval design for seamless phase I/II clinical trials.
    Lin R; Yin G
    Stat Med; 2017 Nov; 36(26):4106-4120. PubMed ID: 28786138
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Toxicity-evaluation designs for phase I/II cancer immunotherapy trials.
    Messer K; Natarajan L; Ball ED; Lane TA
    Stat Med; 2010 Mar; 29(7-8):712-20. PubMed ID: 20213706
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Isotonic designs for phase I trials in partially ordered groups.
    Conaway M
    Clin Trials; 2017 Oct; 14(5):491-498. PubMed ID: 28776422
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Shotgun: A Bayesian seamless phase I-II design to accelerate the development of targeted therapies and immunotherapy.
    Jiang L; Li R; Yan F; Yap TA; Yuan Y
    Contemp Clin Trials; 2021 May; 104():106338. PubMed ID: 33711459
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Modified isotonic regression based phase I/II clinical trial design identifying optimal biological dose.
    Qiu Y; Zhao Y; Liu H; Cao S; Zhang C; Zang Y
    Contemp Clin Trials; 2023 Apr; 127():107139. PubMed ID: 36870476
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Phase I/II dose-finding design for molecularly targeted agent: Plateau determination using adaptive randomization.
    Riviere MK; Yuan Y; Jourdan JH; Dubois F; Zohar S
    Stat Methods Med Res; 2018 Feb; 27(2):466-479. PubMed ID: 26988926
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Bayesian optimal interval design for dose finding in drug-combination trials.
    Lin R; Yin G
    Stat Methods Med Res; 2017 Oct; 26(5):2155-2167. PubMed ID: 26178591
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Bayesian optimization design for finding a maximum tolerated dose combination in phase I clinical trials.
    Takahashi A; Suzuki T
    Int J Biostat; 2021 Apr; 18(1):39-56. PubMed ID: 33818029
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Probability intervals of toxicity and efficacy design for dose-finding clinical trials in oncology.
    Lin X; Ji Y
    Stat Methods Med Res; 2021 Mar; 30(3):843-856. PubMed ID: 33327870
    [TBL] [Abstract][Full Text] [Related]  

  • 30. BOIN-ETC: A Bayesian optimal interval design considering efficacy and toxicity to identify the optimal dose combinations.
    Kakizume T; Takeda K; Taguri M; Morita S
    Stat Methods Med Res; 2024 Apr; 33(4):716-727. PubMed ID: 38444354
    [TBL] [Abstract][Full Text] [Related]  

  • 31. TEPI-2 and UBI: designs for optimal immuno-oncology and cell therapy dose finding with toxicity and efficacy.
    Li P; Liu R; Lin J; Ji Y
    J Biopharm Stat; 2020 Nov; 30(6):979-992. PubMed ID: 32951518
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A Bayesian dose finding design for dual endpoint phase I trials.
    Loke YC; Tan SB; Cai Y; Machin D
    Stat Med; 2006 Jan; 25(1):3-22. PubMed ID: 16013039
    [TBL] [Abstract][Full Text] [Related]  

  • 33. An adaptive dose-finding design incorporating both toxicity and efficacy.
    Zhang W; Sargent DJ; Mandrekar S
    Stat Med; 2006 Jul; 25(14):2365-83. PubMed ID: 16220478
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Checkerboard: a Bayesian efficacy and toxicity interval design for phase I/II dose-finding trials.
    Yin J; Yuan Y
    J Biopharm Stat; 2020 Nov; 30(6):1006-1025. PubMed ID: 32966167
    [TBL] [Abstract][Full Text] [Related]  

  • 35. An adaptive multi-stage phase I dose-finding design incorporating continuous efficacy and toxicity data from multiple treatment cycles.
    Du Y; Yin J; Sargent DJ; Mandrekar SJ
    J Biopharm Stat; 2019; 29(2):271-286. PubMed ID: 30403559
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Bayesian optimal interval design with multiple toxicity constraints.
    Lin R
    Biometrics; 2018 Dec; 74(4):1320-1330. PubMed ID: 29870069
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Dose-finding designs for trials of molecularly targeted agents and immunotherapies.
    Chiuzan C; Shtaynberger J; Manji GA; Duong JK; Schwartz GK; Ivanova A; Lee SM
    J Biopharm Stat; 2017; 27(3):477-494. PubMed ID: 28166468
    [TBL] [Abstract][Full Text] [Related]  

  • 38. TITE-gBOIN-ET: Time-to-event generalized Bayesian optimal interval design to accelerate dose-finding accounting for ordinal graded efficacy and toxicity outcomes.
    Takeda K; Yamaguchi Y; Taguri M; Morita S
    Biom J; 2023 Oct; 65(7):e2200265. PubMed ID: 37309248
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A Bayesian adaptive design for multi-dose, randomized, placebo-controlled phase I/II trials.
    Xie F; Ji Y; Tremmel L
    Contemp Clin Trials; 2012 Jul; 33(4):739-48. PubMed ID: 22426247
    [TBL] [Abstract][Full Text] [Related]  

  • 40. gBOIN-ET: The generalized Bayesian optimal interval design for optimal dose-finding accounting for ordinal graded efficacy and toxicity in early clinical trials.
    Takeda K; Morita S; Taguri M
    Biom J; 2022 Oct; 64(7):1178-1191. PubMed ID: 35561046
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.